Sematrinity
by Sun Pharma · DCGI approved December 2025
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| DCGI status | Approved December 2025 |
| Price (MRP) | ₹750–2,000/month |
| Format | Multi-dose pen |
| Prescription | Schedule H — required |
How Sematrinity compares
Sematrinity is Sun Pharma's type-2-diabetes brand of generic semaglutide, sharing the same active molecule as Noveltreat (Sun Pharma's obesity brand) but labelled and dosed for glycaemic control. Multi-dose pen format simplifies titration for endocrinologists managing T2D dose escalation.
About Sun Pharma
Sun Pharma's dual-brand strategy mirrors Novo Nordisk's Ozempic (T2D) / Wegovy (obesity) approach — same molecule, distinct branding for distinct prescribing populations. Both Sematrinity and Noveltreat received DCGI approval together in December 2025.
Manufacturer announcement
Additional source
Sun Pharma DCGI approval PRGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.